A startup that spun out of research at the University of Maryland School of Medicine was acquired 18 months after forming.
In a deal announced this week, Living Pharma was acquired by Lentigen Technology Inc., a Gaithersburg-based subsidiary of Miltenyi Biotec GmbH. Terms were not disclosed.
Living Pharma’s technology focuses on CAR T-cell therapy, an emerging form of treatment that uses re-engineered versions of a patient’s immune cells to target cancer cells. The technology, invented by UMSOM faculty member Eduardo Davila, is designed to regulate the treatment, and allow the treatment to target multiple kinds of cancer cells.
READ FULL ARTICLE HERE
